HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Discount-Dress.com ... aim of the firm is to increase the company’s online ... introduced a new selection of bridesmaid dresses and announced a ... offer is valid until Dec. 30, 2014. All the dresses ... also inexpensive. , In fact, Discount-Dress.com is very good ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
(Date:11/21/2014)... , Nov. 20, 2014  RedRick Technologies, a ... and reading room environment guidance, has helped the ... radiology reading room, which may also serve as ... Penn Medicine. "In line with ... College of Radiology,s Imaging 3.0 ™ initiative, ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... at the Piper Jaffray 26 th Annual Healthcare Conference in ... at the Piper Jaffray conference is scheduled for 8:00 am EST ... be webcast, and the webcast can be accessed via the Investor ... recording of the webcast will be archived for 30 days on ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
Cached News: